Glycyrrhetic Acid Exerts Positive Effects on Nasal Symptoms and Asthma Control in Allergic Children

Year 2022, Volume: 5 Issue: 3, 73 - 76, 15.12.2022

Maria Angela Tosca Roberta Olcese Claudia Salmaso Valerio Damiani Giorgio Ciprandi

Abstract

Objective: Allergic rhinitis and asthma share an immunoglobulin E-mediated inflammatory reaction following exposure to the causal allergen. Asthma control is associated with rhinitis control. Glycyrrhetic acid is extracted from the licorice and has an anti-inflammatory property. Mannitol is an anti-edema molecule. A medical device contains these components. This study evaluated the medical device efficacy on symptoms and asthma control in children with allergic rhinitis and mild controlled asthma.

Methods: The children took 2 puffs of the medical device for each nostril twice a day for 4 weeks. Symptom severity was evaluated considering the total symptom score and nasal obstruction. Symptom perception was assessed by children and doctors using the visual analog scale. Asthma severity and control were also evaluated. Parents judged the efficacy.

Results: The study included 38 children: 18 (47.4%) females and 20 (52.6%) males; the mean age was 10.2 (±2.15) years. The treatment significantly reduced the severity of all symptoms, including nasal obstruction (P < .001). Both children and doctors perceived a reduction of symptom intensity (P < .001). Parents judged the treatment as effective. Asthma remained mild and controlled.

Conclusions: This pilot study, conducted in clinical practice, showed that intranasal glycyrrhetic acid plus mannitol could reduce nasal symptoms, including obstruction, and maintain asthma control. Therefore, this multicomponent medical device could represent a potential option in children with allergic rhinitis and mild controlled asthma.

Keywords

Allergic rhinitis , asthma , control , symptoms , glycyrrhetic acid , mannitol

References

• Greiwe JC, Bernstein JA. Allergic and mixed rhinitis: diagnosis and natural evolution. J Clin Med. 2019;8(11):11.
• Kuo CRW, Chan R, Lipworth B. Does unified allergic airway disease impact on lung function and Type 2 biomarkers? Allergy Asthma Clin Immunol. 2019;15:75.
• Ciprandi G, Cirillo I, Vizzaccaro A, Milanese M, Tosca MA. Nasal obstruction in patients with seasonal allergic rhinitis: relationships between allergic inflammation and nasal airflow. Int Arch Allergy Immunol. 2004;134(1):34-40 J Clin Med.
• Ciprandi G, Cirillo I, Klersy C, Marseglia GL, Caimmi D, Vizzaccaro A. Nasal obstruction is the key symptom in hay fever patients. Otolaryngol Head Neck Surg. 2005;133(3):429-435.
• Cox L. Approach to patients with allergic rhinitis: testing and treatment. Med Clin North Am. 2020;104(1):77-94.
• Fokkens WJ. Local corticosteroids, why are they not used more / properly? Rhinology. 2019;57(2):81.
• Ciprandi G, Varricchio A. The relevance of the mometasone furoate Nasal Spray Device in clinical practice. J Biol Regul Homeost Agents. 2018;32(4):1051-1054.
• Choi E, Chandran NS, Tan C. Corticosteroid phobia: a questionnaire study using TOPICOP score. Singapore Med J. 2020;61(3):149-153.
• Magna M, Pisetsky DS. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol Med. 2014;20:138-146.
• Sabbadin C, Bordin L, Donà G, Manso J, Avruscio G, Armanini D. Licorice: from pseud ohype raldo stero nism to therapeutic uses. Front Endocrinol. 2019;10:484.
• Cavone L, Cuppari C, Manti S, et al. Increase in the level of proinflammatory cytokine HMGB1 in nasal fluids of patients with rhinitis and its sequestration by glycyrrhizin induces eosinophils cell death. Clin Exp Otorhinolaryngol. 2015;8(2):123-128.
• Passali D, Cappello C, Passali GC, Cingi C, Sarafoleanu C, Bellussi LM. Nasal mucociliary transport time alteration: efficacy of 18 B glycyrrhetinic acid. Multidisc. Resp Med. 2017;12:29.
• Mansi N, D’Agostino G, Scirè AS, et al. Allergic rhinitis in children: A randomized clinical trial targeted at symptoms. Indian J Otolaryngol Head Neck Surg. 2014;66(4):386-393.
• Damiani V, Camaioni A, Viti C, Schillani G, Foltran F, Sciré AS. Short-term efficacy of Narivent in the treatment of nasal congestion. Open Med Dev J. 2012;4(1):66-72.
• Gariuc L, Sandul A, Rusu D, et al. A comparison between mometasone furoate nasal spray and intranasal glycyrrhetic acid in patients with allergic rhinitis: a preliminary study in clinical practice. Acta Biomed. 2020;91(1-S):65-72.
• Ciprandi G, Cirillo I. The lower airway pathology of rhinitis. J Allergy Clin Immunol. 2006;118(5):1105-1109.
• Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: allergic rhinitis. Int Forum Allergy Rhinol. 2018;8:108-352.
• Global initiative for asthma [GINA guidelines]. Global Strategy for Asthma Management and Prevention. Available at: htpp://www.ginasthma.org/. Accessed March 2022.
• Morjaria JB, Caruso M, Emma R, Russo C, Polosa R. Treatment of allergic rhinitis as a strategy for preventing asthma. Curr Allergy Asthma Rep. 2018;18(4):23.
• Enck P, Klosterhalfen S. Placebos and the placebo effect in drug trials. Handb Exp Pharmacol. 2019;260:399-431.
• Damiani V, Camaioni A, Viti C, Scirè AS, Morpurgo G, Gregori D. A single-centre, before-after study of the short- and long-term efficacy of Narivent(®) in the treatment of nasal congestion. J Int Med Res. 2012;40(5):1931-1941.